Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-label, Multi-center Protocol for Patients Who Have Completed a Previous Novartis Sponsored Remibrutinib Study and Are Judged by the Investigator to Benefit From Continued Treatment With Remibrutinib.

Next Previous
Trial Profile

An Open-label, Multi-center Protocol for Patients Who Have Completed a Previous Novartis Sponsored Remibrutinib Study and Are Judged by the Investigator to Benefit From Continued Treatment With Remibrutinib.

Status: Not yet recruiting
Phase of Trial: Phase III

Latest Information Update: 18 Mar 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Remibrutinib (Primary)
  • Indications Food hypersensitivity; Peanut hypersensitivity
  • Focus Registrational; Therapeutic Use
  • Sponsors Novartis Pharmaceuticals

Most Recent Events

  • 11 Mar 2026 New trial record
  • 09 Mar 2026 Status changed from planning to not yet recruiting.
  • 23 Feb 2026 According to a Novartis media release, the company plans to begin the Phase III program in food allergy (FA) in 2026.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top